Table 1 Relationship between the expression of HSPB6 in prostate cancer and clinicopathological parameters.
From: 8-Br-cGMP activates HSPB6 and increases the antineoplastic activity of quinidine in prostate cancer
Characteristics | N | HSPB6-high | HSPB6-low | χ2 | P |
|---|---|---|---|---|---|
Age | |||||
 ≥70 | 62 | 33 | 29 | 0.027 | 0.869 |
 <70 | 58 | 30 | 28 |  |  |
Gleason score | |||||
 ≥8 | 43 | 15 | 28 | 8.339 | 0.004* |
 <8 | 77 | 48 | 29 |  |  |
T classification | |||||
 T3, T4 | 73 | 31 | 42 | 7.525 | 0.006* |
 T1, T2 | 47 | 32 | 15 |  |  |
Lymph node metastasis | |||||
 Present | 41 | 14 | 27 | 8.413 | 0.004* |
 Absent | 79 | 49 | 30 |  |  |
Distant metastasis | |||||
 Present | 52 | 19 | 33 | 9.375 | 0.002* |
 Absent | 68 | 44 | 24 |  |  |